Skip to main content
رجوع
AKBLF logo

ALK-Abelló A/S

جودة البيانات: 100%
ذروة بيع
AKBLF
OTC Healthcare Biotechnology
KWD 32.18
KWD 0.00 (0.00%)
القيمة السوقية: 6.48B
نطاق اليوم
KWD 32.18 KWD 36.10
نطاق 52 أسبوعًا
KWD 19.90 KWD 36.14
حجم التداول
100
متوسط 50 يوم / 200 يوم
KWD 35.21 / KWD 32.30
الإغلاق السابق
KWD 32.18

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 5.4 0.4
P/B 1.0 2.9
ROE % 20.2 3.7
Net Margin % 19.0 3.9
Rev Growth 5Y % 12.6 10.0
D/E 0.1 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 0.000
KWD 0.000 – KWD 0.000
 10 B 0
FY2029 KWD 9.863
KWD 9.772 – KWD 9.948
 10 B 1
FY2028 KWD 7.996
KWD 7.923 – KWD 8.065
 9 B 1

النقاط الرئيسية

Revenue grew 12.61% annually over 5 years — strong growth
Earnings grew 46.54% over the past year
ROE of 20.24% indicates high profitability
Net margin of 18.96% shows strong profitability
Debt/Equity of 0.07 — conservative balance sheet
Generating 1.54B in free cash flow

النمو

Revenue Growth (5Y)
12.61%
Revenue (1Y)13.74%
Earnings (1Y)46.54%
FCF Growth (3Y)131.05%

الجودة

Return on Equity
20.24%
ROIC18.17%
Net Margin18.96%
Op. Margin26.35%

الأمان

Debt / Equity
0.07
Current Ratio3.38
Interest Coverage72.30

التقييم

P/E Ratio
5.42
P/B Ratio1.01
EV/EBITDA3.41
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 13.74% Revenue Growth (3Y) 14.26%
Earnings Growth (1Y) 46.54% Earnings Growth (3Y) 56.76%
Revenue Growth (5Y) 12.61% Earnings Growth (5Y) 52.82%
Profitability
Revenue (TTM) 6.30B Net Income (TTM) 1.19B
ROE 20.24% ROA 13.05%
Gross Margin 65.87% Operating Margin 26.35%
Net Margin 18.96% Free Cash Flow (TTM) 1.54B
ROIC 18.17% FCF Growth (3Y) 131.05%
Safety
Debt / Equity 0.07 Current Ratio 3.38
Interest Coverage 72.30 Dividend Yield 0.00%
Valuation
P/E Ratio 5.42 P/B Ratio 1.01
P/S Ratio 1.03 PEG Ratio 0.91
EV/EBITDA 3.41 Dividend Yield 0.00%
Market Cap 6.48B Enterprise Value 5.66B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 6.30B 5.54B 4.82B 4.51B 3.92B
Net Income 1.19B 815.00M 486.00M 335.00M 219.00M
EPS (Diluted) 5.41 3.68 2.20 1.51 0.99
Gross Profit 4.15B 3.55B 3.04B 2.79B 2.40B
Operating Income 1.66B 1.09B 666.00M 470.00M 292.00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 9.15B 8.25B 6.73B 6.31B 5.83B
Total Liabilities 2.72B 2.87B 2.28B 2.32B 2.35B
Shareholders' Equity 6.43B 5.37B 4.45B 3.99B 3.48B
Total Debt 418.00M 1.19B 765.00M 696.00M 710.00M
Cash & Equivalents 1.24B 589.00M 474.00M 221.00M 194.00M
Current Assets 4.48B 3.29B 2.97B 2.65B 2.40B
Current Liabilities 1.33B 1.95B 1.31B 1.40B 1.39B

درجات الاستراتيجيات

This stock passed the criteria for 7 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#600 of 1051
41
Custom Capital Light Compounder
#86 of 219
46
Custom Contrarian Investing (David Dreman)
#126 of 670
52
Growth Growth Investing (Philip Fisher)
#151 of 156
15
Value Value Investing (Warren Buffett)
#155 of 203
33
Custom Balanced Risk
#101 of 152
42
Custom Lower Risk
#130 of 141
28

النشاط الأخير

دخل Cash Flow Compounder
Mar 24, 2026
دخل Capital Light Compounder
Mar 24, 2026
دخل Contrarian Investing (David Dreman)
Mar 24, 2026
دخل Growth Investing (Philip Fisher)
Mar 24, 2026
دخل Value Investing (Warren Buffett)
Mar 24, 2026
دخل Balanced Risk
Mar 24, 2026
دخل Lower Risk
Mar 24, 2026